New Delhi (NVI): Hyderabad-based Bharat Biotech, which is developing Covaxin, one of the three vaccine candidates against coronavirus, has been given approval by Central Drugs Standard Control Organisation (CDSCO) to conduct skin trials.
The separate clinical trial will see administering the vaccine through the intradermal route, which is just under the skin. The vaccine is currently tested through an intramuscular route, where it is injected directly into the muscle.
Covaxin, developed in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV), has received Drugs Controller General of India (DCGI) approval for Phase I and II human clinical trials. The trials commenced across India from July.
Bharat Biotech is currently conducting a phase I/II clinical trial of Covaxin on 1,125 patients at 12 hospitals across the country, including All India Institute of Medical Sciences in New Delhi and Patna, King George Hospital in Visakhapatnam, Nizam’s Institute of Medical Sciences in Hyderabad and PGIMS in Rohtak.